Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.
Joshua Charles Hansen died at the age of 18 on Jan. 9, 2025 — just three months short of his 19th birthday — due to ...
The foundation hopes to put the funds toward two clinical programs in blood cancers and one preclinical project in solid tumors.
It’s Friday, the day we take a few moments to highlight the good news in Lancaster County and the surrounding region. Some of ...
Logan Barber turned 12 on Saturday, Feb. 8. He wanted to celebrate this milestone by going out with his family. His chosen ...
Data from the first-in-human radioligand-therapy for muscle invasive bladder cancer (MIBC) using Pentixapharm's Lu177-PentixaTher compound will be shown at the American Society of Clinical Oncology's ...
SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology firm specializing in allogeneic CAR T therapies currently valued at approximately $299 million, has published new data ...
Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...
The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...
The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...
GlobalData on MSN8h
TC BioPharm completes dosing in Cohort A of Phase IIb trial for AMLThe trial was designed to evaluate the therapy’s efficacy and safety in treating AML, as well as myelodysplastic syndromes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback